Prelude Therapeutics Inc (Prelude) is a clinical-stage oncology company that provides drug discovery and development for the treatment of cancers. The company pipeline products include PRT3789, PRT2527 and PRT3645 for the indication including solid Tumors, and Heme Malignancies. Its other pipelines include pipeline includes an IV-administered, potent and highly selective SMARCA2 degrader, PRT3789, a preclinical oral SMARCA2 selective degrader, PRT7732, a potent and highly selective CDK9 inhibitor, PRT2527, and a next-generation CDK4/6 inhibitor, PRT3645. The company collaborates with AbCellera Biologics. on an early-stage discovery program. Prelude is headquartered in Wilmington, Delaware, the US.
Headquarters
United States of America
Address
175 Innovation Boulevard, Wilmington, Delaware, 19805
Website
preludetx.com
Telephone
1 302 4671280
No of Employees
128
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PRLD (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-5.5%
(2022 vs 2021)
Market Cap*
$223.5M
* As of and is in US$
Prelude Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| PRT3789: Advanced or Metastatic Solid Tumors |
| PRT2527: Advanced Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company and AbCellera entered into a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer. |
| 2023 | Contracts/Agreements | In March, the company announced a clinical trial collaboration with BeiGene for future evaluation of its investigational CDK9 inhibitor, PRT2527 in combination with BeiGene’s BTK inhibitor, zanubrutinib in hematologic malignancies. |
| 2022 | Regulatory Approval | In October, the company secured approval from U.S. Food and Drug Administration, (FDA) to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT3789. |
Competitor Comparison
| Key Parameters | Prelude Therapeutics Inc | AnaptysBio Inc | Inovio Pharmaceuticals Inc | Constellation Pharmaceuticals Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Wilmington | San Diego | Plymouth Meeting | Cambridge |
| State/Province | Delaware | California | Pennsylvania | Massachusetts |
| No. of Employees | 128 | 117 | 122 | - |
| Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul A. Friedman, M.D. | Chairman | Executive Board | 2016 | 80 |
| Krishna Vaddi, Ph.D. | Chief Executive Officer; Director | Executive Board | 2016 | 57 |
| Bryant D. Lim | Secretary; Chief Financial Officer - Interim; Chief Legal Officer | Senior Management | 2023 | - |
| Michele Porreca | Chief People Officer | Senior Management | 2021 | - |
| Jane Huang, M.D | President; Chief Medical Officer | Senior Management | 2022 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer